AUSAF (Australis Capital) 9-Day RSI: 36.90 (As of Jul. 02, 2026)


What is Australis Capital 9-Day RSI?

Australis Capital AUSAF -95.00% 9-Day RSI is 36.90 as of Jul. 02, 2026.

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2026-07-02), Australis Capital's 9-Day RSI is 36.90.

The industry rank for Australis Capital's 9-Day RSI or its related term are showing as below:

AUSAF's 9-Day RSI is not ranked
in the Drug Manufacturers industry.
Industry Median: 49.87 vs AUSAF: 36.90

Australis Capital  (OTCPK:AUSAF) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

Australis Capital 9-Day RSI Related Terms

AUSAF vs ZTS, CTLT, VTRS: 9-Day RSI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Australis Capital's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Australis Capital 9-Day RSI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Australis Capital's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where Australis Capital's 9-Day RSI falls into.


Australis Capital  (OTCPK:AUSAF) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100–[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 9-Day RSI →
What does a 9-Day RSI of 36.90 mean?
Australis Capital (AUSAF) has a 9-Day RSI of 36.90 as of Jul. 02, 2026.
Is Australis Capital's 9-Day RSI too high?
Australis Capital's current 9-Day RSI is 36.90. The Drug Manufacturers industry median 9-Day RSI is 49.87. Australis Capital's value of 36.90 is 26% below this industry median.
How does Australis Capital's 9-Day RSI compare to ZTS and CTLT?
Australis Capital's 9-Day RSI of 36.90 can be compared against companies in the Drug Manufacturers industry. The industry median 9-Day RSI is 49.87. Australis Capital's value of 36.90 is 26% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 49.87, based on 1,049 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Australis Capital's current 9-Day RSI of 36.90 is 26% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 49.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Australis Capital's current 9-Day RSI is 36.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australis Capital stock overvalued right now?
Australis Capital (AUSAF) has a current 9-Day RSI of 36.90. The current 9-Day RSI is 36.90 and 26% below the Drug Manufacturers industry median of 49.87. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Australis Capital (AUSAF), the current 9-Day RSI is 36.90 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Australis Capital Business Description

Address 376 E. Warm Springs Road, Suite 190, Las Vegas, NV, USA, 89119
Australis Capital Inc operates as a multi-state operator in the cannabis industry in the US. The company is focused on brands and attractive cannabis licenses in states with favorable economics. AUSA is building an MSO based on a unique and very difficult to imitate strategy. Secure access to low-cost but high-quality biomass enables the company to fuel the expansion of its footprint across the US. The company has a rapidly growing footprint in the U.S. in states, such as California, Nevada, Massachusetts, Missouri, Oklahoma, as well as international operations through its subsidiary ALPS, with projects in Europe, Asia and North America.